Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-04-20
2009-08-25
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000, C514S258100, C514S303000, C514S333000, C514S340000, C514S341000, C514S342000, C514S343000, C544S124000, C544S262000, C544S273000, C544S333000, C548S118000, C548S194000, C548S256000
Reexamination Certificate
active
07579355
ABSTRACT:
The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
REFERENCES:
patent: 5506219 (1996-04-01), Robl
patent: 5585388 (1996-12-01), Cosford et al.
patent: 5594011 (1997-01-01), McDonald et al.
patent: 5686470 (1997-11-01), Weier et al.
patent: 6060491 (2000-05-01), Pruitt et al.
patent: 6960584 (2005-11-01), Carling et al.
patent: 7304063 (2007-12-01), Bilodeau et al.
patent: 7414055 (2008-08-01), Duggan et al.
patent: 2002/0127214 (2002-09-01), Hemmings
patent: 2004/0102360 (2004-05-01), Barnett et al.
patent: 2004/0106540 (2004-06-01), Barnett et al.
patent: 2004/0116433 (2004-06-01), Owens et al.
patent: 2004/0122012 (2004-06-01), Owens et al.
patent: 2005/0130977 (2005-06-01), Lindsley et al.
patent: 2005/0159422 (2005-07-01), Lindsley et al.
patent: 2005/0182256 (2005-08-01), Duggan et al.
patent: 2005/0222155 (2005-10-01), Bilodeau et al.
patent: 2005/0288294 (2005-12-01), Duggan et al.
patent: 0356788 (1990-03-01), None
patent: WO 96/15123 (1996-05-01), None
patent: WO 96/23769 (1996-08-01), None
patent: WO 96/24584 (1996-08-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 97/22360 (1997-06-01), None
patent: WO 01/91754 (2001-12-01), None
patent: WO 02/083138 (2002-10-01), None
patent: WO 03/084473 (2003-10-01), None
Tessier et al. “Serum and glucocorticoid . . .” J. Cell. Biochem. v.98, p. 1391-1407 (2006).
Zhao et al. “Discovery of 2,3,5-trisugstituted . . .” Bioorg. Med. Chem. Lett. v.15, p. 905-909 (2005).
Cancer classification p. 1-3 (2005) (internet).
Grever et al. “The national cancer institute . . .” Sem. in Oncology, v. 19, p. 622-638 (1992).
ACTT cell lines description, p. 1-6 (2009) (internet).
Bilodeau, et al. Database on Stn. No. 139:350754, WO 2003/086394.
Barnett, et al. Database on Stn. No. 139:323527, WO 2003/084473 (2003)
Zhao, et al. Biorganic & Medicinal Chemistry Letters, vol. 15 (4), pp. 905-909, Database o Stn. No. 142:211437 (2005).
DeFeo-Jones, et al. Molecular Cancer Therapeutics, vol. 4(2), p. 271-279 (2005).
Lindsley, et al. Bioorganic & Medicinal Chemistry Letters, vol. 15(3), p. 761-764 (2005).
Bilodeau Mark T.
Duggan Mark E.
Hartnett John C.
Lindsley Craig W.
Wu Zhicai
Chang Celia
Leff Matthew A.
Merck & Co. , Inc.
Muthard David A.
LandOfFree
Inhibitors of Akt activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of Akt activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of Akt activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4123485